Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis
NCT ID: NCT07243639
Last Updated: 2025-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2025-10-01
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
NCT05061446
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
NCT04607837
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
NCT06294925
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
NCT03996369
Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
NCT07271069
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
elderly patients (aged 65 years or older) with active ulcerative colitis
Etrasimod administration
2 mg of Etrasimod is orally administered everyday.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etrasimod administration
2 mg of Etrasimod is orally administered everyday.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Showa Inan General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Akira Horiuchi
Chief of Digestive Disease Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Showa Inan General Hospital
Komagane, Nagano, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Etrasimod in elderly UC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.